Labcorp Drug Development (LDD) is experienced in overcoming RA clinical trial challenges. We have and established patient support system, including health education and appointment reminders. LDD Voice of Patient insights are used in trial design to ensure compliance and retention.

Seven drugs have been approved for treatment of chronic hepatitis B virus (HBV), but most patients still require lifelong therapy with virally targeted drugs.

ISPOR Europe 2022 -- Traditionally, tumors have been treated based on their site of origin rather than their specific characteristics.

ISPOR Europe 2022 -- China's near-universal drug coverage has limitations due to high out-of-pocket costs for patients and poor coverage of innovative, premium-priced medicines. To increase access to high-cost innovative drugs, national drug price negotiations were introduced in 2015.

ISPOR Europe 2022 -- Patient engagement in health technology assessment (HTA) appraisals is important to identify unmet needs, ensure the authorisation of safe and effective treatments and enhance the implementation of patient-centered care leading to better health outcomes.

ISPOR Europe 2022 -- Observational studies are not controlled and are subject to confounding factors that could influence outcomes.

ISPOR Europe 2022 -- In 2013, NICE introduced the HST pathway, an alternative to the standard NICE evaluation aimed specifically at technologies for very rare conditions. The pathway considers a broader range of criteria about the benefits and costs than is the case with its appraisals of mainstream drugs and treatments.

ISPOR Europe 2022 -- Immortal time arises when the determination of a patient's treatment status involves a waiting period. A bias is introduced when this period is unaccounted for in the assessment of treatment effectiveness and/or safety.

ISPOR Europe 2022 -- Advanced therapy medicinal products (ATMPs), such as cell and gene therapies, are often associated with single administration and curative potential in many chronic, life-limiting and life-threatening diseases.

Systemic lupus erythematosus (SLE) clinical trials are complex, and, to date, only three compounds have been approved for this condition. There remains some controversy around which outcome measures and endpoints are best for SLE trial design.